Easy-to-use formulations help broaden market penetration in China
TUSTIN, Calif., June 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), (http://www.amdl.com), a leader in specialty pharmaceuticals, announced today its subsidiary Jade Pharmaceutical, Inc. (JPI) anticipates releasing during the 3rd quarter of 2008 two new formulations of its popular Goodnak(R) anti-aging skin care product line. In addition to its high quality injectable formulation, JPI anticipates offering Goodnak in capsules and an easy-to-apply lotion.
Based on general market information, the proposed pricing for these new formulations will be approximately US$40.00 per unit, with 60% gross profit margins. JPI plans to sell both products through existing distribution channels within the Henan, Sichuan, Guizhou, Shanxi, Xinjiang, Gansu, Hunnan, Zhejiang, Fujian, Liaoning and Heilongjiang Provinces of China. Together these regions have a combined population of more than 376 million people. In addition to China, AMDL believes both products will be good candidates for export to the North American and European markets.
According to Gary Dreher, CEO of AMDL, "With the popularity of the Goodnak brand in China, combined with JPI's ability to sell through pre-approved distribution channels, we anticipate sales to exceed well beyond our initial annual sales forecast for Goodnak of $24 million. This is extremely positive news for the market, Company and our shareholders."
Additional information on AMDL, Goodnak and the Company's other pharmaceutical products is available at http://www.amdl.com.
AMDL, Inc. is a global specialty pharmaceutical Company. The Company is
headquartered in Tustin, California with operations in Shenzhen, Jiangxi,
and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI),
AMDL is devoted to the research, devel
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved